OXERVATE Drug Profile

Summary for Tradename: OXERVATE

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for OXERVATE

Recent Clinical Trials for OXERVATE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	NA
Benedetto Falsini	Phase 2
Tufts Medical Center	Phase 1

See all OXERVATE clinical trials

Pharmacology for OXERVATE

Established Pharmacologic Class	Recombinant Human Nerve Growth Factor
Chemical Structure	Nerve Growth Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for OXERVATE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for OXERVATE Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for OXERVATE Derived from Patent Text Search

No patents found based on company disclosures

Oxervate Market Dynamics, Patent Exclusivity, Competition, and Financial Trajectory

Last updated: September 8, 2026

Oxervate, the commercial name for cenegermin-bkbj, is the first FDA-approved treatment for neurotrophic keratitis. Dompé launched the biologic in the United States in 2018 after FDA approval under orphan-drug and biologics pathways. Its commercial outlook is driven by high per-course pricing, limited competition, specialist prescribing, and a narrow diagnosed population.

The principal constraints are diagnosis, reimbursement, six-times-daily administration for eight weeks, and the eventual emergence of biosimilar or competing nerve-growth-factor products. Oxervate’s U.S. biologic exclusivity runs to approximately 2030, while orphan-drug exclusivity runs to February 2025 unless protected by other regulatory or patent rights. Public financial disclosures do not provide a fully audited, product-level Oxervate revenue series.

What is Oxervate and what disease does it treat?

Oxervate is a recombinant form of human nerve growth factor, or rhNGF, supplied as cenegermin-bkbj ophthalmic solution at 0.002%, equivalent to 20 micrograms per milliliter. It is administered as one drop in the affected eye six times daily at two-hour intervals for eight weeks. Each treatment course uses 56 single-use vials. The product is approved for neurotrophic keratitis in adults and, in the United States, pediatric patients aged 2 years and older.[1]

Neurotrophic keratitis results from impaired corneal innervation. The condition can progress from epithelial defects to corneal ulceration, melting, perforation, and vision loss. Causes include herpes simplex or herpes zoster infection, diabetes, neurosurgery, chemical injury, chronic topical drug exposure, and ocular surgery.

Oxervate’s mechanism differentiates it from lubricants, antibiotics, corticosteroids, amniotic membrane products, and surgical interventions. Cenegermin is intended to restore corneal innervation and promote epithelial healing rather than provide only surface protection.

When did Oxervate receive FDA approval?

The FDA approved Oxervate on August 22, 2018, under Biologics License Application 761094. The approval was based on clinical studies showing higher rates of corneal healing compared with vehicle treatment in patients with stage 2 or stage 3 neurotrophic keratitis.[1]

Milestone	Date
FDA orphan-drug designation	Before approval
FDA approval of Oxervate	August 22, 2018
Initial labeled population	Adults with neurotrophic keratitis
Pediatric expansion	Patients aged 2 years and older
FDA regulatory pathway	BLA, orphan drug
Treatment duration	Eight weeks
Dosing frequency	Six times daily

The European Medicines Agency authorized Oxervate in 2017 for adults with moderate or severe neurotrophic keratitis. The European label uses a similar eight-week treatment regimen and includes a repeat-course framework for patients with incomplete response or recurrence under specified conditions.[2]

What is the U.S. exclusivity timeline for Oxervate?

Oxervate has several overlapping forms of protection. The dates below distinguish regulatory exclusivity from patent protection.

Protection	Estimated end point	Commercial relevance
U.S. orphan-drug exclusivity	August 2025	Blocks approval of the same drug for the same indication, subject to statutory exceptions
BPCIA reference-product exclusivity	Approximately August 2030	Prevents FDA approval of a biosimilar for 12 years after first licensure
Patent protection	Patent-specific	Depends on issued claims, terminal disclaimers, adjustments, and litigation
Pediatric exclusivity	Product-specific	Requires confirmation from FDA records before inclusion in a forecast

The orphan designation does not prevent all competition. It generally restricts approval of the same drug for the same disease or condition. It does not block a different active ingredient, a competing biologic, or a biosimilar outside the scope of the orphan designation.

The 12-year reference-product exclusivity under the Biologics Price Competition and Innovation Act is more important for long-range competition. A biosimilar application could be submitted after four years, but approval generally cannot occur before 12 years after first licensure. This places the principal U.S. biosimilar approval window around 2030, subject to statutory interpretation and litigation.[3]

What patents protect Oxervate?

Oxervate is a biologic, so its U.S. protection is not analyzed through a simple small-molecule Orange Book listing. The relevant rights can include patents covering:

• Recombinant human nerve growth factor;
• Formulations and stabilizing excipients;
• Ophthalmic delivery;
• Treatment of neurotrophic keratitis;
• Corneal wound healing;
• Manufacturing and purification processes;
• Dosing schedules and repeat treatment.

FDA biologic records and the Purple Book provide regulatory information, but they do not provide a single public substitute for a complete freedom-to-operate review. Patent term calculations also depend on patent-term adjustment, patent-term extension, terminal disclaimers, continuation practice, and claim scope.

Is Oxervate listed in the Orange Book?

Oxervate is not analyzed like a conventional small-molecule drug under the Hatch-Waxman Orange Book framework. It was approved as a biologic under a BLA. The relevant competition pathway is the BPCIA, which governs biosimilar applications and patent-information exchanges.

A generic drug company cannot normally file an ANDA seeking approval of a conventional generic version of cenegermin-bkbj as though Oxervate were a small molecule. A future competitor would generally require a biosimilar application, a new BLA, or another biologic regulatory pathway.

Are there Paragraph IV challenges to Oxervate?

No widely reported U.S. Paragraph IV litigation against Oxervate is identified in the publicly available regulatory and litigation record through mid-2024. Paragraph IV is a Hatch-Waxman mechanism and is not the normal route for a biosimilar challenge to a BLA product.

A future biosimilar sponsor would more likely use the BPCIA patent-disclosure and litigation framework. That process can involve a patent dance, declaratory actions, infringement litigation, and negotiated launch timing.

How strong is the Oxervate patent estate?

The Oxervate estate has commercial strength from the combination of regulatory exclusivity, biologic manufacturing complexity, orphan-disease economics, and clinical differentiation. Patent strength is harder to assess from public information without a claim-by-claim review of issued patents and continuations.

The strongest practical barriers are likely to be:

1. Manufacturing reproducibility for a recombinant protein used in an ophthalmic product.
2. Formulation stability and container-closure requirements.
3. Clinical comparability for corneal healing and safety.
4. Limited patient numbers for a biosimilar development program.
5. Prescriber and payer familiarity with the branded product.
6. Potential method-of-use, formulation, or process claims that extend beyond the core composition claims.

The weaker areas are disease diagnosis and therapeutic substitution. Physicians can use amniotic membrane, autologous serum, therapeutic contact lenses, tarsorrhaphy, corneal neurotization, topical insulin, or other off-label approaches. These alternatives do not need to establish biosimilarity to Oxervate.

What is the commercial price and revenue exposure of Oxervate?

Oxervate has an exceptionally high gross cost relative to conventional ophthalmic drugs because a full course requires 56 single-use vials and specialty handling. Public pricing references have placed the U.S. list cost of an eight-week course near or above $100,000, with the exact figure changing over time and depending on the source and contracting arrangement.[4]

The commercial price is not the same as net revenue. Actual manufacturer realization depends on:

• Commercial rebates;
• Government discounts;
• Specialty-pharmacy fees;
• Patient assistance;
• Prior-authorization denials;
• Free-drug programs;
• Payer mix;
• Course completion;
• Repeat-treatment utilization.

Dompé is privately held and does not provide the same level of segment reporting as a public pharmaceutical company. Public disclosures have not established a consistently reported, audited annual Oxervate revenue series. Product-level revenue estimates should therefore be treated as market estimates rather than reported company financials.

What is driving Oxervate’s market growth?

Oxervate’s growth depends less on broad population expansion than on increased diagnosis and treatment penetration.

Diagnosis and referral

Neurotrophic keratitis is underdiagnosed because symptoms can be less severe than the visible corneal damage. Reduced corneal sensation can delay referral and obscure disease progression. Increased use of corneal sensitivity testing, imaging, and specialist referral supports case identification.

Specialist adoption

Cornea specialists are the primary commercial gatekeepers. Adoption is stronger when physicians view Oxervate as a treatment that can prevent surgery, restore the epithelium, and preserve vision.

Reimbursement

Coverage commonly requires confirmation of disease severity, failed conventional treatment, and documentation of corneal epithelial defects. Prior authorization can delay initiation and reduce conversion from diagnosis to treatment.

Treatment burden

Six daily doses for eight weeks create adherence and storage challenges. The product requires refrigerated handling, thawing or preparation under labeled conditions, and disposal of single-use containers. These factors increase specialty-pharmacy involvement and can reduce completed courses.

Repeat treatment

Repeat courses may create additional revenue in recurrent or incompletely healed disease, particularly in patients with persistent nerve dysfunction. Repeat use also faces payer scrutiny and may not be reimbursed uniformly across markets.

How does Oxervate compare with competing treatments?

Treatment	Regulatory status	Main role	Competitive effect
Oxervate	FDA-approved biologic	Disease-directed therapy for neurotrophic keratitis	Direct branded benchmark
Preservative-free lubricants	Supportive care	Surface protection	Used before and with Oxervate
Therapeutic contact lenses	Device-based care	Epithelial protection	Alternative or adjunct
Amniotic membrane	Procedure/device product	Wound healing and surface coverage	Can substitute in selected cases
Autologous serum tears	Off-label or compounded	Trophic support	Lower-cost alternative
Tarsorrhaphy	Surgery	Exposure reduction and healing	Used in severe or refractory disease
Corneal neurotization	Surgery	Nerve restoration	Specialized option
Topical insulin	Off-label	Epithelial healing	Emerging low-cost alternative
Investigational NGF products	Development-stage	Potential direct competition	Long-term competitive risk

Oxervate has the strongest regulatory position, but its high cost creates room for lower-cost interventions. Competitive pressure is therefore likely to appear first through treatment substitution and payer management rather than through a conventional generic launch.

What is the biosimilar risk for Oxervate?

Near-term U.S. biosimilar risk is limited by the biologic exclusivity period and the small patient population. Long-term risk is credible because cenegermin is a recombinant protein and the FDA has an established biosimilar pathway for biologics.

A biosimilar sponsor would face several challenges:

• Small clinical trial recruitment;
• Difficult endpoint selection;
• Corneal healing variability;
• Immunogenicity and device or container comparability;
• Limited physician experience with biosimilar ophthalmic biologics;
• High manufacturing and analytical costs;
• Uncertain market size relative to development expense.

The first competitive entrants may instead be new products with different mechanisms, lower administration burden, or less expensive formulations. A once-daily regenerative ophthalmic product could compete more effectively than a direct biosimilar if it demonstrates similar clinical outcomes.

Which companies are challenging Oxervate?

No company has established a widely commercialized U.S. competing rhNGF product against Oxervate through mid-2024. The competitive field consists of:

• Surgical and procedural ophthalmology providers;
• Manufacturers of amniotic membrane products;
• Compounding pharmacies supplying autologous serum or off-label products;
• Developers of regenerative ophthalmic medicines;
• Potential future biosimilar manufacturers;
• Specialty pharmacies and distributors competing for product access and patient services.

Dompé’s principal commercial advantage is first-mover status in a rare corneal disease. Its principal exposure is that physicians already have multiple non-equivalent but clinically accepted alternatives.

What licensing deals support Oxervate?

Dompé developed and commercialized cenegermin through its ophthalmology business and has built distribution and market-access arrangements around Oxervate. Public information does not establish a single large, publicly reported licensing transaction that would independently determine the product’s financial trajectory.

The underlying intellectual-property and development history includes academic and scientific work on nerve growth factor, but commercial rights and current ownership must be separated from early discovery contributions. Regulatory ownership, patent ownership, manufacturing rights, and distribution rights may reside with different entities by jurisdiction.

What is the likely Oxervate launch and generic-entry scenario?

Base case

Oxervate retains premium pricing, expands diagnosis, and grows through specialist adoption and repeat treatment. The product remains the standard pharmacologic treatment through the late 2020s.

Downside case

Payer restrictions, treatment burden, and low diagnosis rates limit growth. Physicians continue using lower-cost procedures and compounded alternatives. Net price declines even if gross sales increase.

Biosimilar-entry case

A biosimilar or follow-on biologic reaches the U.S. market around or after 2030. Price erosion is initially moderate because the patient population is small and prescriber switching is limited. Greater erosion occurs if multiple manufacturers enter or if payers create preferred formulary tiers.

Innovation-displacement case

A competing therapy provides comparable nerve regeneration with fewer doses, simpler storage, or a lower cost. Such a product could pressure Oxervate before direct biosimilar entry.

What is the geographic market opportunity?

The United States is the most commercially important market because of high specialty-drug pricing and established reimbursement infrastructure. Europe offers broader geographic coverage but generally lower net prices and more centralized health-technology assessment.

Market expansion depends on regulatory approval, reimbursement, local ophthalmology capacity, and distribution of refrigerated specialty products. Countries with limited cornea-specialist access may have substantial clinical need but lower near-term commercial penetration.

Key Takeaways

• Oxervate is cenegermin-bkbj, the first FDA-approved treatment specifically for neurotrophic keratitis.
• FDA approval occurred on August 22, 2018, under BLA 761094.
• Orphan-drug exclusivity runs approximately through August 2025.
• Biologic reference-product exclusivity generally extends to approximately August 2030.
• Oxervate is a BLA biologic, so biosimilar and BPCIA analysis is more relevant than Hatch-Waxman Paragraph IV analysis.
• The eight-week course requires 56 single-use vials and has a gross U.S. cost near or above $100,000 based on public pricing references.
• Dompé’s private ownership limits visibility into audited, product-level revenue and margin data.
• The major commercial growth levers are diagnosis, specialist adoption, reimbursement, and repeat treatment.
• The major risks are payer restrictions, treatment burden, off-label alternatives, and future competing biologics or regenerative products.
• No broadly reported U.S. Paragraph IV challenge or commercial Oxervate biosimilar launch was identified through mid-2024.

FAQs

Is Oxervate considered a specialty drug?

Yes. Oxervate is generally distributed through specialty-pharmacy channels because it is a refrigerated biologic with complex administration, prior-authorization requirements, and a high per-course cost.

Can Oxervate be used for corneal ulcers unrelated to neurotrophic keratitis?

Its FDA indication is neurotrophic keratitis. Use for other corneal ulcers may be off-label and depends on physician judgment, disease cause, and payer policy.

Does Oxervate permanently restore corneal nerves?

Clinical treatment promotes corneal healing and can improve corneal nerve function, but the degree and durability of nerve recovery vary. Recurrence can occur when the underlying nerve injury persists.

What would make a competing Oxervate product commercially successful?

Lower cost alone may not be sufficient. Strong competitors would likely combine comparable corneal-healing outcomes with fewer daily doses, simpler storage, easier administration, or broad payer coverage.

Is Oxervate revenue likely to decline immediately after orphan exclusivity ends?

Not necessarily. Orphan exclusivity expiration does not automatically create a generic or biosimilar product. Revenue pressure would depend on patent status, regulatory filings, competing products, payer behavior, and actual market entry.

References

1. U.S. Food and Drug Administration. (2018). Oxervate (cenegermin-bkbj) ophthalmic solution prescribing information. FDA.

2. European Medicines Agency. (2017). Oxervate: EPAR product information. EMA.

3. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. FDA.

4. Drugs.com. (2024). Oxervate pricing, coupons, and patient assistance information. Drugs.com.